GlaxoSmithKline will pay $105 million [small cost of doing big business] to settle charges that it unlawfully promoted its asthma drug Advair and antidepressants Paxil and Wellbutrin. The payment settles charges brought by 45 state attorneys general.
The attorneys general alleged GSK also illegally marketed a second antidepressant drug, Wellbutrin, to children without FDA approval. GSK also unlawfully marketed Wellbutrin as an “off-label” drug for weight loss and to treat attention deficit disorder, addiction, anxiety and bi-polar disorder.
But it was not fined for using anti-depressants to treat chronic pain?
All Things Chronic 